Reverb, Royalmount Laboratories to Develop Advanced Bispecific Antibodies
Reverb’s novel Amplify•R™ platform combines bispecific antibody engineering with data-driven modelling of antibody-tissue interaction to amplify endogenous cytokines and redirect them to tissues of interest.
CRO Organizations | 14/11/2024 | By Aishwarya | 411
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy